Keros Therapeutics, Inc. (KROS) Earnings History
Net Loss8 years of earnings data (2018–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Keros Therapeutics, Inc. (KROS) Earnings Overview
As of June 21, 2026, Keros Therapeutics, Inc. (KROS) reported trailing twelve-month net income of -$85M, reflecting +146.0% year-over-year growth. The company earned $-2.25 per diluted share over the past four quarters, with a net profit margin of 35.7%.
Looking at the long-term picture, KROS's historical earnings data spans multiple years. The company achieved its highest annual net income of $87M in fiscal 2025, representing a new all-time high.
Keros Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$506M net income), KRYS ($225M net income, 52.6% margin), DAWN (-$107M net income, -67.8% margin), KROS has comparable earnings metrics. Compare KROS vs IMVT →
KROS Earnings vs Peers
Earnings metrics vs comparable public companies
KROS Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $87M | +146.4% | $71M | $2.30 | 35.7% | 28.9% |
| 2024 | -$187M | -22.5% | -$211M | $-5.00 | -5277.5% | -5939.0% |
| 2023 | -$153M | -46.2% | -$170M | $-5.20 | -101319.2% | -112543.7% |
| 2022 | -$105M | -78.2% | -$115M | $-4.15 | - | - |
| 2021 | -$59M | -29.5% | -$56M | $-2.52 | -292.3% | -280.5% |
| 2020 | -$45M | -267.5% | -$47M | $-2.93 | - | - |
| 2019 | -$12M | -824.6% | -$11M | $-1.39 | -123.4% | -105.6% |
| 2018 | -$1M | - | -$2M | $-0.15 | -13.4% | -16.9% |
Download Data
Export KROS earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
KROS — Frequently Asked Questions
Quick answers to the most common questions about buying KROS stock.
What is KROS earnings per share (EPS)?
KROS trailing twelve-month (TTM) diluted EPS is $-2.25, reflecting +146.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2018 to 2025 is available in the table on this page.
What is Keros Therapeutics, Inc.'s net income?
Keros Therapeutics, Inc. (KROS) trailing twelve-month net income is $-85M as of 2025. Earnings grew +146.0% year-over-year.
Is KROS profitable?
KROS is not currently profitable on a TTM basis, reporting a net loss of $-85M. Net margin is +35.7%. Investors should monitor for a return to profitability.
What is KROS's earnings growth rate?
KROS compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2018 to 2025.
What are KROS's profit margins?
Keros Therapeutics, Inc. net profit margin is +35.7%, operating margin is +28.9%, and gross margin is +99.4%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +19.9%.
Is KROS growing earnings?
Yes, KROS earnings are accelerating — EPS growth of +146.0% exceeds the 5-year CAGR of N/A. TTM net income reached $-85M. Earnings momentum is strengthening.
What was KROS's best earnings year?
Keros Therapeutics, Inc.'s highest annual net income on record is $87M, achieved in fiscal year 2025. Earnings history on this page spans 2018 to 2025 and includes all annual and quarterly figures.
What were KROS's earnings last quarter?
KROS's most recent reported quarter was Q1 2026. Net income was $-24M with diluted EPS of $-0.63. For a full breakdown of all quarters, see the quarterly earnings table on this page.